EBioMedicine (Jul 2023)

Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastasesResearch in context

  • Eftychia Chatziioannou,
  • Jana Roßner,
  • Thazin New Aung,
  • David L. Rimm,
  • Heike Niessner,
  • Ulrike Keim,
  • Lina Maria Serna-Higuita,
  • Irina Bonzheim,
  • Luis Kuhn Cuellar,
  • Dana Westphal,
  • Julian Steininger,
  • Friedegund Meier,
  • Oltin Tiberiu Pop,
  • Stephan Forchhammer,
  • Lukas Flatz,
  • Thomas Eigentler,
  • Claus Garbe,
  • Martin Röcken,
  • Teresa Amaral,
  • Tobias Sinnberg

Journal volume & issue
Vol. 93
p. 104644

Abstract

Read online

Summary: Background: Recent advances in digital pathology have enabled accurate and standardised enumeration of tumour-infiltrating lymphocytes (TILs). Here, we aim to evaluate TILs as a percentage electronic TIL score (eTILs) and investigate its prognostic and predictive relevance in cutaneous melanoma. Methods: We included stage I to IV cutaneous melanoma patients and used hematoxylin-eosin-stained slides for TIL analysis. We assessed eTILs as a continuous and categorical variable using the published cut-off of 16.6% and applied Cox regression models to evaluate associations of eTILs with relapse-free, distant metastasis-free, and overall survival. We compared eTILs of the primaries with matched metastasis. Moreover, we assessed the predictive relevance of eTILs in therapy-naïve metastases according to the first-line therapy. Findings: We analysed 321 primary cutaneous melanomas and 191 metastatic samples. In simple Cox regression, tumour thickness (p 12.2% was associated with longer progression-free survival (p = 0.037) and melanoma-specific survival (p = 0.0038) in patients treated with anti-PD-1-based immunotherapy. In multiple Cox regression, lactate dehydrogenase (p < 0.0001) and eTILs ≤12.2% (p = 0.0130) were significantly associated with unfavourable melanoma-specific survival. Interpretation: Assessment of TILs is prognostic in primary melanoma samples, and the eTILs complements staging. In therapy-naïve metastases, eTILs ≤12.2% is predictive of unfavourable survival outcomes in patients receiving anti-PD-1-based therapy. Funding: See a detailed list of funding bodies in the Acknowledgements section at the end of the manuscript.

Keywords